Celcuity says Revtorpyk boosts progression-free survival in breast cancer
What it means
- What to watch: Approvals and strong trial data can reprice a drugmaker quickly — especially when one product is most of the company.
- How the stock is trading: $CELC +3.92% in the latest session.
- Timing: It dropped mid-session, while New York was open, so the move beside it may already include the market's first reaction.
Where the stock stands
$CELC last traded at $67.81, +3.92% on the session. That puts it 55% shy of its 52-week high of $151.02 and 27% clear of its low of $53.54 — in the lower part of the range. Over the year it has ranged 182% from low to high: a very wide band; big swings are routine for this one, not news. These are latest-session quotes, not live prices — the live tape is on the $CELC page.
How much coverage it is getting
This is the only story Wook has logged on $CELC in the last 30 days — a quiet name that just got a headline. 12 related stories — same name or same desk — are lined up beside this one if you want the whole thread.
The bigger picture
Healthcare stories turn on approvals, trial data and pricing: one FDA decision or trial readout can swing a single drugmaker hard, while drug-pricing policy moves the whole group at once. Wook's supply-chain scanner has Health Care reading calm today: no unusual stress in the filings and disclosures it watches.
Coming up
$CELC earnings in 16 days. These were on the calendar before this story and are not caused by it.
What to watch next
The $CELC page has the full chart, the filings and the valuation model behind every figure here. Because one outlet dominates the coverage, reading another outlet on the same story is the quickest check on whether it is being confirmed or just repeated. Wook AI, above, can pull live figures and run the numbers on request — how far $CELC is from its high, or how this week's coverage compares.
How this analysis was made
Seeking Alpha published it, and Wook filed it under Healthcare & Pharma. It reads bullish at medium severity because of “boost” in the wording, with nothing on the bearish side to offset it. It was matched to $CELC. The publisher gave no preview text, and nothing has been written in to fill the gap.
The tone and severity labels come from a fixed word list — no editor, no AI, no crystal ball — so they describe how a story is worded, not what happens next. They are not a forecast or a recommendation, and a same-day move does not mean this story caused it. Not investment advice.
Discussion
No one has weighed in yet. Start the discussion on this story.
What happened after this published
Seeking Alpha published this on October 26, 2026. $CELC has moved +1.66% ($66.71 to $67.81). Measured from the first print available after publication, against the latest available quote. This comparison does not isolate the story's effect.